Background
Regulation of glucose homeostasis
Physiological mechanisms regulating insulin secretion from the pancreatic β-cells
Transient (causes of) hyperinsulinaemic hypoglycaemia
Congenital hyperinsulinaemic hypoglycaemia
1. Transient causes of HH • Maternal diabetes mellitus (gestational and insulin-dependent) • Use of maternal intravenous dextrose during labour • Intrauterine growth restriction • Perinatal asphyxia • Rhesus isoimmunisation | |
2. Genetic causes of HH • Channelopathies ○ ABCC8 ○ KCNJ11 • Metabolopathies ○ GLUD1 ○ HADH ○ GCK ○ SLC16A1 ○ HNF1A ○ HNF4A ○ UCP2 ○ HK1 ○ PGM1 ○ PMM2 | |
3. Metabolic causes of HH • Congenital disorders of glycosylation • Tyrosinaemia type 1 | |
4. Syndromic causes of HH • Beckwith-Wiedemann • Kabuki • Trisomy 13 • Central hypoventilation syndrome • Leprechaunism (insulin resistance syndrome) • Mosaic Turner • Sotos • Usher • Timothy • Costello | |
5. Miscellaneous causes of HH • Postprandial HH ▪ Insulin gene receptor mutation ▪ Dumping syndrome ▪ Noninsulinoma pancreatogenous hypoglycaemia syndrome (adults) ▪ Insulin autoimmune syndrome (mostly adults) ▪ Bariatric surgery (adults) ▪ Insulinoma • Non-islet cell tumour hypoglycaemia (adults) • Factitious hypoglycaemia • Drug-induced |
Genetics of Hyperinsulinaemic Hypoglycaemia
Pancreatic β-cell KATP channel defects
Glutamate dehydrogenase (GLUD1) mutations and Hyperinsulinism-hyperammonaemia syndrome (HI/HA)
Hydroxyacyl-CoA dehydrogenase (HADH) mutations and congenital HH
Glucokinase (GCK) mutations and congenital HH
Exercise-induced Hyperinsulinaemic Hypoglycaemia
Hepatocyte nuclear factor 1A&4A (HNF1A&4A) and congenital HH
Mutations in the uncoupling protein 2(UCP2) gene and congenital HH
Hexokinase 1 (HK1) gene mutations and congenital HH
Phosphoglucomutase 1 (PGM1) gene mutations and congenital HH
Phosphomannomutase 2(PMM2) gene mutations and congenital HH
Clinical presentation of hyperinsulinaemic hypoglycaemia
Diagnosis and investigations of HH
Diagnostic criteria | • Plasma glucose <3 mmol/l with: • Detectable serum insulin • Detectable C-peptide (In endogenous HH) • Suppressed/low serum ketone bodies • Suppressed/low serum fatty acids |
Supportive evidences (when diagnosis is in doubt or difficult): | • Glucose infusion rate > 8 mg/kg/min • Positive glycaemic (>1.5 mmol/L) response to intramuscular/ intravenous glucagon • Positive glycaemic response to a subcutaneous/intravenous dose of octreotide • Low serum levels of IGFBP1 [insulin negatively regulates the expression of IGFBP1] • Suppressed branch chain (leucine, isoleucine and valine) amino acids • Provocation tests (leucine loading or exercise testing) may be needed in some patients • Supressed/undetectable urine ketone • Normal lactic acid • Normal plasma hydroxybutyrylcarnitinea
• Normal ammoniab
• Appropriate counterregulatory hormone responsec
-Cortisol > 20 mcg/dl (500 nmol/l) -Growth hormone > 7 ng/ml In the neonatal period if the hypoglycaemia persists for >48 h this will require investigation |
Hyperinsulinaemic hypoglycaemia management
Emergency management
Parenteral glucose infusion
Glucagon administration
Frequent feeding
Long-term management
Diazoxide
Route | Dose | Mode of action | Side effects | |
---|---|---|---|---|
Conventional medicines | ||||
Diazoxide |
Oral
| 5–20 mg/kg/day, in 3 divided doses | Bind to SUR1 subunit of KATPchannels, opens the channels and inhibits insulin secretion Requires an intact KATP channel activity to work properly | Common: Water and salt retention, hypertrichosis, loss of appetite Rare: Cardiac failure, hyperuricaemia, blood dyscrasias (bone marrow suppression, anaemia, eosinophilia etc.), paradoxical hypoglycaemia |
Chlorothiazide | Oral | 7–10 mg/kg/day, in 2 divided doses | Prevents fluid retention, synergistic effects with diazoxide on KATP channels to inhibit insulin secretion | Hyponatraemia, hypokalaemia |
Nifedipine | Oral | 0.25–2.5 mg/kg/day, in 2–3 divided doses | Inhibits Ca-channels of the β-cell membrane | Hypotension |
Octreotide | s.c | 5–35 μg/kg/day, divided to 3–4 doses or continuous subcutaneous infusion | Activation of SSTR-2 and SSTR-5 inhibits calcium mobilization and acetylcholine activity, and decreases insulin gene promoter activity, reduces insulin biosynthesis and insulin secretion. | Acute: Anorexia, nausea, abdominal discomfort, diarrhoea, drug induced hepatitis, elevated liver enzyme, long QT syndrome, tachyphylaxis, necrotizing enterocolitis Long-term: Decreases intestinal motility, bile sludge and gallstone, suppression of pituitary hormones (Growth hormone, TSH) |
Glucagon | s.c/i.m bolus or s.c/i.v infusion | 0.02 mg/kg/dose or 5–10 μg/kg/h infusion | G-protein coupled activation of adenylate cyclase, increases cAMP, Induces glycogenolysis and gluconeogenesis | Nausea, vomiting, skin rash and rebound hypoglycaemia in high doses (>20 μg/kg/h) due to paradoxical activation of insulin secretion |
New medicines | ||||
Rapamycin (sirolimus, everolimus) | Oral | An initial dose of 1 mg/m2 per day may require dose adjustment according to blood sirolimus concentration usually to keep between 5 and 15 ng/ml | mTOR inhibitor. Inhibits insulin release and β-cell proliferation through different mechanism which have not been clarified yet | Immune suppression, mucositis, hyperlipidemia, elevation of liver enzyme, thrombocytosis, impaired immune response to BCG vaccine |
Octreotide LAR/ Lanreotide | Deep s.c | Total 4 weekly dose of octreotide given every 4 weekly or 15–60 mg/every 4 weekly | These long acting somatostatin analogues have similar effects as daily multidose octreotide. | Similar to daily multiple injection octreotide. However, long-term follow up is not known yet |